Management of cutaneous T-cell lymphomas: Recommendations of the French Cutaneous Lymphoma Group;Prise en charge des lymphomes T cutanés: Recommandations du Groupe franais d'étude des lymphomes cutanés

Annales de Dermatologie et de Venereologie

Volumn 137, Issue 10, 2010, Pages 611-621

  Beylot Barry, M ^a,j   Dereure, O ^b   Vergier, B ^a,j   Barete, S ^c   Laroche, L ^d   MacHet, L ^e   Delfau Larue, M H ^f   D'Incan, M ^g   Grange, F ^h   Ortonne, N ^f   Merlio, J P ^a,j   Bagot, M ⁱ  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

^c HÔPITAL TENON   (France)

^d AVICENNE HOSPITAL   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h SERVICE DE DERMATOLOGIE   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j UNIVERSITÉ DE BORDEAUX   (France)

more..

Author keywords

Primary cutaneous lymphoma; Recommendations; Staging; T cell lymphoma; Treatment

Indexed keywords

ALEMTUZUMAB; BEXAROTENE; CARMUSTINE; CD30 ANTIGEN; CHLORMETHINE; DOXORUBICIN; GEMCITABINE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CUTANEOUS T CELL LYMPHOMA; HISTOPATHOLOGY; HUMAN; MEDICAL LITERATURE; MYCOSIS; NOTE; PUVA; RISK BENEFIT ANALYSIS; SEZARY SYNDROME; T CELL LYMPHOMA;

EID: 77957783162     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2010.06.021     Document Type: Short Survey

References (52)

1. E.S. Jaffe The 2008 WHO classification of lymphomas: implications for clinical practice and translational research Hematology 1 2009 523 531
2. R. Willemze, E.S. Jaffe, G. Burg, L. Cerroni, E. Berti, and S.H. Swerdlow WHO-EORTC classification for cutaneous lymphomas Blood 105 2005 3768 3785
3. F. Trautinger, R. Knobler, R. Willemze, K. Peris, R. Stadler, and L. Laroche EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome Eur J Cancer 42 2006 1014 1030
4. H. Bachelez, M. Bagot, M. Beylot-Barry, A. Claudy, F. Grange, and J.J. Grob Algorithme thérapeutique pour les lymphomes T cutanés Ann Dermatol Venereol 132 2005 5S43 44
5. R. Dummer, C. Assaf, M. Bagot, R. Gniadecki, A. Hauschild, and R. Knobler Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 43 2007 2321 2329
6. S.J. Whittaker, and F.M. Foss Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma Cancer Treat Rev 33 2007 146 160
7. R. Willemze, M. Dreyling, and ESMO Guidelines Working Group Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 4 2009 115 118
8. H.M. Prince, S. Whittaker, and R.T. Hoppe How we treat mycosis fungoides and Sézary syndrome Blood 114 2009 4337 4353
9. http://sircamt.canceraquitaine.org/rca/documents/referentiels/ RefLymphomesCutanes.pdf
10. E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, and R. Knobler Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 110 2007 1713 1722 (Pubitemid 47443880)
11. M.H. Delfau-Larue, S. Dalac, and E. Lepage Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides Blood 92 1998 3376 3380
12. M. Beylot-Barry, V. Sibaud, R. Thiebaut, B. Vergier, C. Beylot, and M. Delaunay Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independant prognostic factor un primary cutaneous T-cell lymphomas J Invest Dermatol 117 2001 920 926
13. M.H. Delfau-Larue, L. Laroche, J. Wechsler, E. Lepage, C. Lahet, and M. Asso-Bonnet Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma Blood 96 2000 2987 2992
14. E. Poszepczynska-Guigné, V. Schiavon, M. D'Incan, H. Echchakir, P. Musette, and N. Ortonne KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome J Invest Dermatol 122 2004 820 823
15. R. Kumar, Y. Xiu, H.M. Zhuang, and A. Alavi 18F-fluorodeoxyglucose- positron emission tomography in evaluation of primary cutaneous lymphoma Br J Dermatol 155 2006 357 363
16. E.Y. Tsai, A. Taur, L. Espinosa, A. Quon, D. Johnson, and S. Dick Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography Arch Dermatol 142 2006 577 584
17. V. Sibaud, M. Beylot-Barry, and R. Thiebault Bone marrow histopathologic and molecular staging in epidermotropic T-cell lymphoma Am J Clin Pathol 119 2003 414 423
18. M. Beylot-Barry, M. Parrens, M. Delaunay, R. Thiebault, B. Vergier, and A. DeMascarel Is bone marrow biopsy necessary in patients with mycosis fungoides and Sezary syndrome? A histological and molecular study at diagnosis and during follow-up Br J Dermatol 152 2005 1378 1379
19. J. de Quatrebarbes, E. Esteve, M. Bagot, P. Bernard, M. Beylot-Barry, and M. Delaunay Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study Arch Dermatol 141 2005 1117 1120
20. E. Estve, and F. Grange Chlormethine (Caryolysine), carmustine (Bicnu) Ann Dermatol Venereol 134 2007 992 996
21. O. Dereure, E. Picot, C. Comte, D. Bessis, and B. Guillot Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results Dermatology 218 2009 1 6
22. E.D. Recio, B. Zambrano, M.L. Alonso, E. de Eusebio, M. Martín, and J. Cuevas Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature Int J Dermatol 47 2008 410 413
23. M. Duvic, A.G. Martin, Y. Kim, E. Olsen, G.S. Wood, and C.A. Crowley Phase 2 and 3 clinical trial of oral bexarotene [Targretin capsules] for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593
24. M.L. Lokitz, and H.K. Wong Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides Photodermatol Photoimmunol Photomed 23 2007 255 257
25. E. Papadavid, C. Antoniou, V. Nikolaou, M. Siakantaris, T.P. Vassilakopoulos, and A. Stratigos A Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides Am J Clin Dermatol 9 2008 169 173
26. M. Beylot-Barry Bexarotene Ann Dermatol Venereol 134 2007 987 991
27. E. Goujon, G. Truc, T. Petrella, P. Maingon, G. Jeudt, and E. Collet Electronthérapie corporelle totale du mycosis fongoïde aux stades précoces : 68 cas Ann Dermatol Venereol 136 2009 249 255
28. M. Duvic, K. Hymes, P. Heald, D. Breneman, A.G. Martin, and P. Myskowski Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471 (Pubitemid 32391217)
29. R.A. Abbott, S.J. Whittaker, S.L. Morris, R. Russell-Jones, T. Hung, and S.J. Bashir Bexarotene therapy for mycosis fungoides and Sézary syndrome Br J Dermatol 160 2009 1299 1307
30. S. Pulini, S. Rupoli, G. Goteri, N. Pimpinelli, R. Alterini, and A. Tassetti Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas Haematologica 92 2007 686 689
31. G. Quereux, S. Marques, J.M. Nguyen, C. Bedane, M. D'Incan, and O. Dereure Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome Arch Dermatol 144 2008 727 733
32. K. Jidar, S. Ingen-Housz-Oro, M. Beylot-Barry, C. Paul, D. Chaoui, and M. Sigal-Grinberg Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases Br J Dermatol 161 3 2009 660 663
33. O. Awar, and M. Duvic Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine Oncology 73 2007 130 135
34. R.F. Duarte, N. Schmitz, O. Servitje, and A. Sureda Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma Bone Marrow Transplant 41 2008 597 604
35. C.E. Introcaso, B. Leber, K. Greene, R. Ubriani, A.H. Rook, and E.J. Kim Stem cell transplantation in advanced cutaneous T-cell lymphoma J Am Acad Dermatol 58 2008 645 649
36. P.A. Wu, Y.H. Kim, P.W. Lavori, R.T. Hoppe, and K.E. Stockerl-Goldstein A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome Biol Blood Marrow Transplant 15 2009 982 990
37. M. Duvic, M. Donato, B. Dabaja, H. Richmond, L. Singh, and W. Wei Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome J Clin Oncol 28 2010 2365 2372
38. J. Scarisbrick, P. Taylor, U. Holtick, Y. Makar, K. Douglas, and G. Berlin UK consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic GVHD Br J Dermatol 158 2008 659 678
39. R. Knobler, M.L. Barr, D.R. Couriel, J.L. Ferrara, L.E. French, and P. Jaksch Extracorporeal photopheresis: past, present, and future J Am Acad Dermatol 61 2009 652 665
40. A. Ranki Bexarotene combination therapy for patients with Sézary syndrome Dermatol Clin 26 Suppl. 1 2008 55 57
41. M.G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, and F. Lisa Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients Haematologica 92 2007 784 794
42. A. Molina, J. Zain, D.A. Arber, M. Angelopolou, M. O'Donnell, and J. Murata-Collins Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides J Clin Oncol 23 2005 6163 6171
43. C. Muniesa, T. Estrach, R.M. Pujol, F. Gallardo, P. Garcia-Muret, and J. Climent Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases J Am Acad Dermatol 62 2010 418 426
44. M.W. Bekkenk, F.A. Geelen, P.C. van Voorst Vader, F. Heule, M.L. Geerts, and W.A. van Vloten Primary and secondary cutaneous CD30[+] lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment Blood 95 2000 3653 3656
45. B. Vergier, M. Beylot-Barry, K. Pulford, P. Michel, J. Bosq, and A. de Muret Statistical evaluation of diagnostic and prognostic features of cutaneous CD30+ lymphoproliferations. Study of 65 cases Am J Surg Pathol 22 1998 1192 1202
46. T. Nijsten, Curiel-Lewandrowskic, and M.E. Kadin Lymphomatoid Papulosis in children. A retrospective cohort study of 35 cases Arch Dermatol 140 2004 306 312
47. H.S. Zachkeim, C. Jones, P.E. LeBoit, M. Kashani-Sabet, T.H. McCalmont, and J. Zehnder Lymphomatoid papulosis associated with mycosis fungoides J Am Acad Dermatol 49 2003 620 623
48. Y.H. Kim, R. Willemze, N. Pimpinelli, S. Whittaker, E.A. Olsen, and A. Ranki TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 110 2007 479 484 (Pubitemid 47105384)
49. M.F. Benner, and R. Willemze Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients Br J Dermatol 159 2008 1148 1151
50. C. Querfeld, T.M. Kuzel, J. Guitart, and S.T. Rosen Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy Oncology 21 2007 689 696
51. M.E. Kadin Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders Oncology 23 2009 1158 1164
52. F.J. Kaye, P.A. Bunn, S.M. Steinberg, J.L. Stocker, D.C. Ihde, and A.B. Fischmann Randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides N Engl J Med 321 1989 1784 1790